Zeleciment rostudirsen (z-rostudirsen)

Duchenne muscular dystrophy

Also known as DYNE-251

Manufacturer: Dyne Therapeutics
Regulatory submission: BLA submitted May 2026
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Exon-skipping antisense oligonucleotides

1 evidence topic · 1 source

Eteplirsen therapeutic class

“antisense oligonucleotide” (opens the source at this quote in a new tab)